WaveMan
WaveMan · Company
QURE · Uniqure N.V.
> Search tickers & screens ⌘K
LIVE
← All companies

QURE uniQure (QURE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001590560
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
176
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $4.1M priced

What the filings say about QURE

Insiders, 180 days
-$17.9M net sold
11 sellers · 0% of sales under a 10b5-1 plan

uniQure insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, uniQure N.V. insiders sold a net $17.9M of stock across 180 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kapusta Matthew C
CEO, Managing Director
SELL
2026-07-07 SECtraded 2026-07-02
9,200
$408.8K
-50.2%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Jun 25, 2026.
  • The trade is 1.7% of the 531,109 shares held after it.
  • 10 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, Managing Director Kapusta Matthew C sold about $408.8K of QURE on Jul 2, 2026; 10 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Kapusta Matthew C
CEO, Managing Director
SELL
2026-07-07 SECtraded 2026-07-02
4,282
$194.5K
-50.2%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Jun 25, 2026.
  • The trade is 0.8% of the 526,827 shares held after it.
  • 10 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, Managing Director Kapusta Matthew C sold about $194.5K of QURE on Jul 2, 2026; 10 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Kapusta Matthew C
CEO, Managing Director
SELL
2026-07-07 SECtraded 2026-07-02
7,600
$348.8K
-50.2%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Jun 25, 2026.
  • The trade is 1.5% of the 519,227 shares held after it.
  • 10 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, Managing Director Kapusta Matthew C sold about $348.8K of QURE on Jul 2, 2026; 10 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Abi-Saab Walid
Chief Medical Officer
SELL
2026-07-02 SECtraded 2026-06-30
10,000
$464.6K
-47.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 26, 2026.
  • The trade is 5.9% of the 168,235 shares held after it.
  • 10 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Abi-Saab Walid sold about $464.6K of QURE on Jun 30, 2026; 10 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Abi-Saab Walid
Chief Medical Officer
SELL
2026-07-02 SECtraded 2026-06-30
20,000
$928.0K
-47.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 26, 2026.
  • The trade is 13.5% of the 148,235 shares held after it.
  • 10 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Abi-Saab Walid sold about $928.0K of QURE on Jun 30, 2026; 10 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
180 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 175 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$17.9M over 180 days
below 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
176 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
-40.6% year over year
below 77% of Pharma & Biotech
Margin
-1236.0% net margin
below 88% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.2% of the float short (float per yahoo 2026-10-27) · 3.8 days to cover · settled 2026-10-15
more than 83% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 38 in the prior 90
Why it matters
The absence is the signal: 38 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch QURE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-63.5%12M
-85%-50%-16%+19%2025-102025-122026-022026-042026-062026-082026-10 2026-06-17 · Kapusta Matthew C sold $2.5M2026-06-18 · Kapusta Matthew C sold $1.9M2026-06-17 · Kapusta Matthew C sold $1.5M2026-06-17 · Kapusta Matthew C sold $1.5M2026-06-25 · Kapusta Matthew C sold $1.4M2026-06-17 · Kapusta Matthew C sold $1.0M2026-06-30 · Abi-Saab Walid sold $928.0K2026-06-30 · Kaye Jack sold $792.1K2026-05-08 · Abi-Saab Walid sold $627.5K2026-06-17 · Kapusta Matthew C sold $563.6K2025-11-04 · Kaye Jack sold $540.2K2026-05-08 · Abi-Saab Walid sold $500.0K2026-06-30 · Abi-Saab Walid sold $464.6K2026-06-11 · O'Keefe Kylie sold $431.2K2025-11-06 · Gut Robert sold $431.2K2025-11-06 · Gut Robert sold $425.7K2026-01-12 · Gut Robert sold $422.2K2026-07-02 · Kapusta Matthew C sold $408.8K2026-07-02 · Kapusta Matthew C sold $348.8K2026-03-02 · Kapusta Matthew C sold $342.6K2026-06-24 · Kapusta Matthew C sold $334.8K2025-11-04 · Kaye Jack sold $333.7K2025-11-04 · Kaye Jack sold $303.6K2026-02-25 · Kapusta Matthew C sold $295.3K2026-06-15 · Balachandran Madhavan sold $278.5K2026-06-17 · Kapusta Matthew C sold $263.2K2026-06-17 · Balachandran Madhavan sold $249.3K2026-06-18 · Kapusta Matthew C sold $232.8K2026-06-17 · Kaye Jack sold $225.4K2026-06-17 · Balachandran Madhavan sold $205.2K2026-01-12 · Gut Robert sold $195.8K2026-07-02 · Kapusta Matthew C sold $194.5K2026-06-30 · Kaye Jack sold $190.9K2026-01-09 · Kaye Jack sold $174.3K2026-02-25 · KLEMT CHRISTIAN sold $148.3K2026-06-15 · Potts Jeannette sold $144.9K2026-03-04 · Kapusta Matthew C sold $132.1K2026-03-02 · KLEMT CHRISTIAN sold $124.7K2026-03-04 · KLEMT CHRISTIAN sold $108.7K2026-03-02 · Potts Jeannette sold $85.4K2026-06-10 · Gut Robert sold $81.4K2026-06-03 · Kaye Jack sold $79.4K2026-07-02 · Kapusta Matthew C filed to sell $951.9K2026-06-30 · Abi-Saab Walid filed to sell $1.4M2026-06-30 · Kaye Jack filed to sell $983.0K2026-06-26 · Abi-Saab Walid filed to sell $67.2K2026-06-25 · Kapusta Matthew C filed to sell $1.4M2026-06-24 · Kapusta Matthew C filed to sell $334.8K2026-06-18 · Kapusta Matthew C filed to sell $1.9M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns QURE: institutional holders (13F)

13F holdings, latest reported quarter
Avoro Capital Advisors LLC
6,727,777 sh
$309.9M
JPMORGAN CHASE & CO
4,867,755 sh
$230.8M
RTW INVESTMENTS, LP
3,941,572 sh
$181.5M
STATE STREET CORP
2,903,825 sh
$133.8M
Aberdeen Group plc
2,848,117 sh
$131.2M

Congress trades in QURE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

QURE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Kapusta Matthew C
Filed 2026-07-02
$951.9K
Abi-Saab Walid
Filed 2026-06-30
$1.4M
Kaye Jack
Filed 2026-06-30
$983.0K
Abi-Saab Walid
Filed 2026-06-26
$67.2K
Kapusta Matthew C
Filed 2026-06-25
$1.4M

QURE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X Genomics & Biotechnology ETF
$889.8K position · as of 2026-05-31
1.6%
Invesco Dorsey Wright Healthcare Momentum ETF
$3.5M position · as of 2026-07-31
1.5%
PROFUND VP BIOTECHNOLOGY
$488.1K position · as of 2026-06-30
1.0%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$994.3K position · as of 2026-07-31
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
$3.5M position · as of 2026-07-31
0.7%
DIAMOND HILL INTERNATIONAL FUND
$804.3K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Kapusta
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.3M
$7.2M
$1.9M
-34%
+20%
2024
$3.1M
$9.9M
$1.5M
-52%
-10%
2023
$6.6M
-$1.4M
$2.7M
-81%
-8%
2022
$5.6M
$7.0M
$2.4M
-37%
-11%
2021
$5.1M
$1.6M
$2.3M
-43%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $17.9M sold by insiders over 180 days, 176 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

QURE financials

Revenue growth
-40.6%
XBRL, annual
Net margin
-1236.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$18.1M
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
-1,155%
net income over revenue, 2025-04-01 to 2026-03-31
Free cash flow, TTM
-$172.6M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Debt to equity
0.41x
long-term 2026-03-31 plus current 2018-09-30 (91 months older than the period end); equity 2026-03-31
Cash flow to debt
-2.82x
TTM operating cash flow over long-term 2026-03-31 plus current 2018-09-30 (91 months older than the period end)
Return on equity
-228.3%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets
-30.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-29.8%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.3B
market value at close 2026-10-26 on 2026-05-01 shares, plus long-term 2026-03-31 plus current 2018-09-30 (91 months older than the period end), minus cash 2026-03-31
FCF yield
-12.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$16.1M$27.1M$15.8M$106.5M
Operating income-$185.3M-$184.3M-$282.9M-$143.2M
Net income-$199.0M-$239.6M-$308.5M-$126.8M
EPS (diluted)-3.46-4.92-6.47-2.71
Operating cash flow-$178.0M-$182.7M-$145.9M-$145.1M
Cash$80.2M$158.9M$241.4M$228.0M
Long-term debt$49.7M$51.3M$101.7M$102.8M
SEC XBRL, fiscal years, as known on 2026-10-28

QURE Stock Sonar score 6/7 axes

Find similar shapesCompare

QURE ranks highest on institutional and government (86th percentile) and profitability (48th), and lowest on insider conviction (5th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
48
Inputs
  • Return on equity-228.3% · 15 pct, sector of 545
  • Return on assets-30.2% · 60 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-29.8% · 68 pct, sector of 576
Financial health
37
Inputs
  • Debt to equity0.41x · 36 pct, sector of 352
  • Cash flow to debt-2.82x · 38 pct, sector of 371
Growth
23
Inputs
  • Revenue growth, YoY-40.6% · 23 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
5
Inputs
  • Net Form 4 buying (codes P and S), 180d-$17.9M · 11 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
86
Inputs
  • Funds adding, latest quarter176 · 86 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
24
Inputs
  • Short interest, % of float+15.2% · 24 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

QURE filings, in plain words

Are uniQure insiders buying or selling QURE?

In the 180 days to 2026-10-28, uniQure insiders were net sellers, a net $17.9M across purchases and sales reported on Form 4, by 11 sellers.

Read the full summary

In the 180 days to 2026-10-28, uniQure insiders were net sellers of QURE, a net $17.9M across purchases and sales reported on Form 4 by 11 sellers. None of the 38 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies